This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...
Bernstein SocGen Group has revised its price target for Merck (NYSE:MRK) shares, bringing it down to $95 from the previous $110 while maintaining a Market Perform rating. Analyst Courtney Breen cited ...
Humana forecast annual profit slightly below Wall Street estimates on Tuesday, signaling that costs from its ...
Die Merck KGaA befindet sich in fortgeschrittenen Verhandlungen zum Kauf des amerikanischen Krebsspezialisten SpringWorks ...
We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...
SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.
Hosted on MSN1d
Merck Stock Heads For 5th Day Of Losses As TD Cowen Downgrades On Gardasil Woes, But Retail Holds StrongShares of Merck & Co. Inc. fell more than 0.5% on Monday afternoon, tracking their fifth consecutive decline in the worst ...
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
SpringWorks Therapeutics shares rose 36% after Reuters reported Germany's Merck KGaA is in advanced talks to buy the company. Shares were trading around $54.66. The stock is up 16% over the last year ...
Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback